Both in Biotechnology
Relay Therapeutics vs Denali Therapeutics
Over the past year RLAY returned +162.8% and DNLI returned +40.5%; their daily moves had a correlation of 0.33.
RLAY +162.8% DNLI +40.5%Growth of $1, one year, split-adjusted
| Metric | RLAY | DNLI |
|---|---|---|
| Price | $18.03 | $20.96 |
| Market cap | $3.95B | $3.35B |
| Today | +3.38% | +7.76% |
| 1 month | −3.8% | +8.7% |
| 6 months | +39.6% | +2.7% |
| Year to date | +113.1% | +27.0% |
| 1 year | +159.8% | +36.5% |
| Revenue growth (YoY) | −48.3% | — |
| Gross margin | 100.0% | 97.4% |
| Net margin | −23916.3% | −3539.2% |
| P/E (TTM) | — | — |
| Price / sales | 381.8× | 929.6× |
| Net cash | $910.9M | $705.0M |
| Dividend yield | — | — |
| Volatility (60d) | 49.2% | 41.2% |
| Short % of float | 27.9% | 11.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).